Drug intelligence / Profile preview

SII Bivalent

Development stage: Unknown
Lead developer: Novavax
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SII Bivalent is a bivalent vaccine developed by Novavax. It is designed to provide immunity against SARS-CoV-2 by containing antigens from both the ancestral strain of SARS-CoV-2 and the B.1.351 (Beta) variant. The vaccine is adjuvanted with Matrix-M1 adjuvant to enhance the immune response. It is administered via intramuscular injection.

Targets

ACE2 (Angiotensin-converting enzyme 2)SARS-CoV-2 spike

Beyond the preview

Go deeper on SII Bivalent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SII Bivalent.

Explore the full profile